glp-1 receptor agonists should be avoided in patients with Impact of GLP- 1 Agonist Therapy High Risk for Sarcopenia | Current Nutrition Reports GLP-1 Receptor Agonists for the

doi: 10.1038/nm.3009 44 CoskunTSloopKWLoghinCAlsina-FernandezJUrvaSBokvistKBet al

GLP-1 RAs are currently being explored for use in various new areas, such as cardiovascular disease, non-alcoholic steatohepatitis (NASH), Alzheimer's disease, and chronic kidney disease

For millions of people who have experienced the frustration of losing weight only to regain it later, this research offers an intriguing new perspective on why long term weight management can be so difficult

However, it is postulated from preclinical data that incorporating GCG receptor agonism may reduce food intake and increase resting energy expenditure, potentially enhancing efficacy

Cosmetic effects like Ozempic face (a thinner, gaunt appearance from rapid fat loss in the face) and temporary hair shedding have also been reported

GLP-1 Drugs: Demand Surges in a Long-Established Market The market for GLP-1 drugs is projected to reach $180 billion in 2034, according to Morningstar Equity Research